Seguimiento y análisis de la realización de la desescalada en el tratamiento con carbapenemes
- Sadyrbaeva Dolgova, Svetlana
- Carmen Hidalgo Tenorio Director
- Miguel Angel Calleja Hernández Director
Defence university: Universidad de Granada
Fecha de defensa: 04 June 2020
- José Hernández Quero Chair
- Miguel Ángel López Ruz Secretary
- María Díez Aguilar Committee member
- Carolina Alarcón Payer Committee member
- Ana Maria Sanchez Diaz Committee member
Type: Thesis
Abstract
1. The prescription of carbapenems is appropriate in more than half of the cases. De-escalation in carbapenem therapy is performed in almost half of the total prescriptions and half of the appropriate prescriptions. 2. De-escalation does not affect in-hospital mortality or 30-day mortality rates. 3. De-escalation in carbapenem therapy does not extend hospital stay nor increases the rate of readmission after 30 days. 4. Pharmacist recommendations for carbapenem de-escalation in complicated UTIs are safe and do not worsen the patient’s clinical outcomes. Performing de-escalation in patients with UTI reduces the duration of hospital stay. 5. Recommendations agreed with the PROA team are well accepted by prescribing physicians and are one of the factors associated with the performance of de-escalation, together with the appropriate carbapenem prescription.